<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750126</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0039</org_study_id>
    <nct_id>NCT00750126</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>RICE</acronym>
  <official_title>Feasibility Study on Allogeneic Hematopoietic Stem Cell Transplantation Following Fludarabine-Busulfan-ALS-based Reduced-intensity Conditioning in Children With Hematological Malignancy or Solid Tumor Not Responding to Standard Therapy or for Which the Indication for Allograft is Maintained But Cannot be Carried Out Due to the Toxicity Involved in Myeloablative Conditioning.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      To assess the engraftment of hematopoietic stem cells following reduced-intensity&#xD;
      conditioning in children presenting with solid tumors or hematological malignancy by&#xD;
      evaluating post-transplantation chimerism and hematological reconstitution.&#xD;
&#xD;
      To study acute and/or chronic graft-versus-host reaction (incidence and severity) and immune&#xD;
      reconstitution, post-transplantation To study the effectiveness of the protocol on tumor&#xD;
      response.&#xD;
&#xD;
      To study overall survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary criterion&#xD;
&#xD;
        -  Hematological reconstitution and chimerism post-transplantation&#xD;
&#xD;
      Secondary criteria&#xD;
&#xD;
        -  Adverse effects, graft-related mortality at D90 and at 12 months, incidence and severity&#xD;
           of acute and/or chronic GVH reactions&#xD;
&#xD;
        -  Analysis of variations in post-transplantation immunological function profiles&#xD;
&#xD;
        -  Median duration of response in therapy-responsive patients and median duration of&#xD;
           stability in stabilized patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Anticipated">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary criterion - Hematological reconstitution and chimerism post-transplantation</measure>
    <time_frame>post-transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary criteria - Adverse effects, graft-related mortality at D90 and at 12 months, incidence and severity of acute and/or chronic GVH reactions</measure>
    <time_frame>post-transplantation</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Hematologic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, Busulfan, Thymoglobulin</intervention_name>
    <description>study :&#xD;
acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation&#xD;
the effectiveness of the protocol on tumor response&#xD;
overall survival</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged less than 20 years old&#xD;
&#xD;
          -  Lansky score &gt; 60%&#xD;
&#xD;
          -  Life expectancy greater than 2 months&#xD;
&#xD;
          -  Diagnoses:&#xD;
&#xD;
             3- Solid tumor or hematological malignancy remaining unresponsive to the reference&#xD;
             strategies according to French best practices in pediatrics.&#xD;
&#xD;
             4- Malignancies for which allografting is the recognized indication but is&#xD;
             contraindicated with myeloablative conditioning.&#xD;
&#xD;
          -  Usual criteria for allogeneic grafting (pre-graft profile)&#xD;
&#xD;
          -  Having a HLA-identical sibling donor for HLA-A, HLA-B and HLA-DR antigens or a HLA&#xD;
             mismatch on only one antigen, or having a 10/10 pheno-identical donor, or compatible&#xD;
             cord blood.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient presenting rapidly-progressive malignancy&#xD;
&#xD;
          -  In cases where the potential donor is related, sibling presenting contraindication&#xD;
             against hematopoietic stem cell donation&#xD;
&#xD;
          -  Unable to sufficiently understand the treatment and its consequences, even after&#xD;
             explanation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paillard Catherine, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lacarin Patrick</last_name>
    <phone>04.73.75.11.95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Paillard Catherine</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paillard Catherine, Dr</last_name>
      <email>cpaillard@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>September 9, 2008</study_first_submitted>
  <study_first_submitted_qc>September 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2008</study_first_posted>
  <last_update_submitted>January 18, 2011</last_update_submitted>
  <last_update_submitted_qc>January 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Catherine PAILLARD</name_title>
    <organization>CHU Clermont-Ferrand</organization>
  </responsible_party>
  <keyword>Allograft</keyword>
  <keyword>Children</keyword>
  <keyword>malignancy</keyword>
  <keyword>Reduced Intensity Conditioning</keyword>
  <keyword>Fludarabin</keyword>
  <keyword>Busulfex</keyword>
  <keyword>Thymoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

